Intralesional therapy for psoriasis

References

• Ghorpade AK. Naevoid blaschkoid psoriasis. Indian J Dermatol Venereol Leprol. 2010;76:449.
   PubMedGoogle Scholar
• Arnold AW, Happle R, Itin PH. Superimposed linear psoriasis unmasked by therapy with adalimumab. Eur J Dermatol. 2010;20:573–574.
   PubMedGoogle Scholar
• Kirby JS, Miller CJ. Intralesional chemotherapy for nonmelanoma skin cancer: a practical review. J Am Acad Dermatol. 2010;63:689–702.
   PubMed Web of Science ®Google Scholar
• Good LM, Miller MD, High WA. Intralesional agents in the management of cutaneous malignancy: a review. J Am Acad Dermatol. 2011;64:413–422.
   PubMed Web of Science ®Google Scholar
• Richards RN. Update on intralesional steroid: focus on dermatoses. J Cutan Med Surg. 2010;14:19–23.
   PubMedGoogle Scholar
• Chan CS, Van Voorhees AS, Lebwohl MG, Korman NJ, Young M, Bebo BF Jr, et al. Treatment of severe scalp psoriasis: from the medical board of the national psoriasis foundation. J Am Acad Dermatol. 2009;60:962–971.
   PubMed Web of Science ®Google Scholar
• Handa S. Newer trends in the management of psoriasis at difficult to treat locations: scalp, palmoplantar disease and nails. Indian J Dermatol Venereol Leprol. 2010;76:634–644.
   PubMed Web of Science ®Google Scholar
• Goette DK, Morgan AM, Fox BJ, Horn RT. Treatment of palmoplantar pustulosis with intralesional triamcinolone injections. Arch Dermatol. 1984;120:319–323.
   PubMedGoogle Scholar
• Jiaravuthisan MM, Sasseville D, Vender RB, Murphy F, Muhn CY. Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol. 2007;57:1–27.
   PubMed Web of Science ®Google Scholar
• de Berker D. Management of nail psoriasis. Clin Exp Dermatol. 2000;25:357–362.
   PubMed Web of Science ®Google Scholar
• de berker DAR, Lawrence CM. A simplified protocol of steroid injection for psoriatic nail dystrophy. Br J Dermatol. 1998;138:90–95.
   PubMed Web of Science ®Google Scholar
• Jiaravuthisan MM, Sasseville D, Vender RB, Murphy F, Muhn CY. Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol. 2007;57:1–27.
   PubMed Web of Science ®Google Scholar
• Sarıcaoglu H, Arife Oz, Turan H. Nail psoriasis successfully treated with intralesional methotrexate: case report. Dermatology. 2011;222:5–7.
   PubMed Web of Science ®Google Scholar
• Sánchez-Regaña M, Sola-Ortigosa J, Alsina-Gibert M, Vidal-Fernández M, Umbert-Millet P. Nail psoriasis: a retrospective study on the effectiveness of systemic treatments (classical and biological therapy). J Eur Acad Dermatol Venereol. 2011;25:579–586.
   PubMed Web of Science ®Google Scholar
• Lee JY. Severe 20-nail psoriasis successfully treated by low dose methotrexate. Dermatol Online J. 2009;15:8.
   Google Scholar
• Amor KT, Ryan C, Menter A. The use of cyclosporine in dermatology: part I. J Am Acad Dermatol. 2010;63:925–946.
   PubMedGoogle Scholar
• Baker BS, Powles AV, Savage CR, McFadden JP, Valdimarsson H, Fry L. Intralesional cyclosporin in psoriasis: effects on T lymphocyte and dendritic cell subpopulations. Br J Dermatol. 1989;120:207–213.
   PubMed Web of Science ®Google Scholar
• Powles AV, Baker BS, McFadden J, Rutman AJ, Griffiths CE, Fry L, et al. Intralesional injection of cyclosporin in psoriasis. Lancet. 1988;1:537.
   PubMed Web of Science ®Google Scholar
• Ho VC, Griffiths CE, Ellis CN, Gupta AK, McCuaig CC, Nickoloff BJ, et al. Intralesional cyclosporine in the treatment of psoriasis. a clinical, immunologic, and pharmacokinetic study. J Am Acad Dermatol. 1990;22:94–100.
   PubMed Web of Science ®Google Scholar
• Burns MK, Ellis CN, Eisen D, Duell E, Griffiths CE, Annesley TM, et al. Intralesional cyclosporine for psoriasis. relationship of dose, tissue levels, and efficacy. Arch Dermatol. 1992;128:786–790.
   PubMedGoogle Scholar
• Roux CH, Breuil V, Valerio L, Amoretti N, Brocq O, Albert C, et al. Etanercept Compared to Intraarticular Corticosteroid Injection in Rheumatoid Arthritis: Double-blind, Randomized Pilot Study. J Rheumatol. 2011; [Epub ahead of print].
   Google Scholar
• Zeichner JA, Stern DW, Lebwohl M. Treatment of necrobiosis lipoidica with the tumor necrosis factor antagonist etanercept. J Am Acad Dermatol. 2006;54(3 Suppl 2):S120–S121.
   Google Scholar
• Gattu S, Busse K, Bhutani T, Chiang C, Nguyen T, Becker E, et al. Psoriasis responds to intralesional injections of alefacept and may predict systemic response to intramuscular alefacept: Interim results of a single-arm, open-label study. J Dermatolog Treat. 2011; [Epub ahead of print].
   PubMedGoogle Scholar
• Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, et al. Botulinum toxin as a biological weapon: medical and public health management. JAMA. 2001;285:1059–1070.
   PubMed Web of Science ®Google Scholar
• Zanchi M, Favot F, Bizzarini M, Piai M, Donini M, Sedona P. Botulinum toxin type-A for the treatment of inverse psoriasis. J Eur Acad Dermatol Venereol. 2008;22:431–436.
   PubMedGoogle Scholar
• Wallengren J, Bartosik J. Botulinum toxin type A for neuropathic itch. Br J Dermatol. 2010;163:424–426.
   PubMed Web of Science ®Google Scholar
• Salardini A, Richardson D, Jabbari B. Relief of intractable pruritus after administration of botulinum toxin A (botox): a case report. Clin Neuropharmacol. 2008;31:303–306.
   PubMedGoogle Scholar
• Heckmann M, Heyer G, Brunner B, Plewig G. Botulinum toxin type A injection in the treatment of lichen simplex: an open pilot study. J Am Acad Dermatol. 2002;46:617–619.
   PubMed Web of Science ®Google Scholar
• Chroni E, Monastirli A, Tsambaos D. Botulinum toxin for inverse psoriasis? J Eur Acad Dermatol Venereol. 2008;22:431–436.
   PubMedGoogle Scholar
• Swartling C, Naver H, Lindberg M, Anveden I. Treatment of dyshidrotic hand dermatitis with intradermal botulinum toxin. J Am Acad Dermatol. 2002;47:667–671.
   PubMed Web of Science ®Google Scholar
• Fogh K, Søgaard H, Herlin T, Kragballe K. Improvement of psoriasis vulgaris after intralesional injections of 15-hydroxyeicosatetraenoic acid (15-HETE). J Am Acad Dermatol. 1988;18(2 Pt 1):279–285.
   PubMedGoogle Scholar
• Longley DB, Harkin DP, Johnston PG. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3:330–338.
   PubMed Web of Science ®Google Scholar
• Fredriksson T. Topically applied fluorouracil in the treatment of psoriatic nails. Arch Dermatol. 1974;110:735–736.
   PubMedGoogle Scholar
• de Jong EM, Menke HE, van Praag MC, van De Kerkhof PC. Dystrophic psoriatic fingernails treated with 1% 5-fluorouracil in a nail penetration-enhancing vehicle: a double-blind study. Dermatology. 1999;199:313–318.
   PubMed Web of Science ®Google Scholar
• Pearlman DL, Youngberg B, Engelhard C. Weekly psoriasis therapy using intralesional fluorouracil. J Am Acad Dermatol. 1987;17:78–82.
   PubMedGoogle Scholar
• Lowe NJ, Nychay S, Orenberg EK, Korey A. Intradermal fluorouracil and epinephrine injectable gel for treatment of psoriatic plaques. Arch Dermatol. 1995;131:1340–1341.
   PubMedGoogle Scholar
• Muir T., Kirsten M., Fourie P, Dippenaar N, Ionescu GO. Intralesional bleomycin injection (IBI) treatment for haemangiomas and congenital vascular malformations. Pediatr Surg Int. 2004;19:766–773.
   PubMed Web of Science ®Google Scholar
• Omidvari S, Nezakatgoo N, Ahmadloo N, Mohammadianpanah M, Mosalaei A. Role of intralesional bleomycin in the treatment of complicated hemangiomas: prospective clinical study. Dermatol Surg. 2005;31:499–501.
   PubMedGoogle Scholar
• Saitta P, Krishnamurthy K, Brown LH. Bleomycin in dermatology: a review of intralesional applications. Dermatol Surg. 2008;34:1299–1313.
   PubMed Web of Science ®Google Scholar
• Rimbaud P, Meynadier J, Ravoire G, Guilhou JJ, Barnéon G. Trial of a new antimitotic agent in the treatment of psoriasis: bleomyoin. Bull Soc Fr Dermatol Syphiligr. 1971;78:464–467.
   PubMedGoogle Scholar
• Aldenhoven M, Barlo NP, Sanders CJ. Therapeutic strategies for epidemic Kaposi's sarcoma. Int J STD AIDS. 2006;17:571–578.
   PubMed Web of Science ®Google Scholar
• Kaplan L, Abrams D, Volberding P. Treatment of Kaposi's sarcoma in acquired immunodeficiency syndrome with an alternating vincristine- vinblastine regimen. Cancer Treat Rep. 1986;70:1121–1122.
   PubMedGoogle Scholar
• Brambilla L, Bellinvia M, Tourlaki A, Scoppio B, Gaiani F, Boneschi V. Intralesional vincristine as first-line therapy for nodular lesions in classic Kaposi sarcoma: a prospective study in 151 patients. Br J Dermatol. 2010;162:854–859.
   PubMed Web of Science ®Google Scholar
• Korn BS, Park DJ, Kikkawa DO. Intralesional Mitomycin-C for the Treatment of Conjunctival Kaposi Sarcoma. Ophthal Plast Reconstr Surg. 2010; [Epub ahead of print].
   Google Scholar
• Bailey JN, Waite AE, Clayton WJ, Rustin MH. Application of topical mitomycin C to the base of shave-removed keloid scars to prevent their recurrence. Br J Dermatol. 2007;156:682–686.
   PubMedGoogle Scholar
• Stewart CE 4th,, Kim JY. Application of mitomycin-C for head and neck keloids. Otolaryngol Head Neck Surg. 2006;135:946–950.
   PubMedGoogle Scholar
• Sanders KW, Gage-White L, Stucker FJ. Topical mitomycin C in the prevention of keloid scar recurrence. Arch Facial Plast Surg. 2005;7:172–175.
   PubMedGoogle Scholar
• Cagiano R, Bera I, Vermesan D, Flace P, Sabatini R, Bottalico L, et al. Psoriasis disappearance after the first phase of an oncologic treatment: a serendipity case report. Clin Ter. 2008;159:421–425.
   PubMedGoogle Scholar
• Barabas K, Milner R, Lurie D, Adin C. Cisplatin: a review of toxicities and therapeutic applications. Vet Comp Oncol. 2008;6:1–18.
   PubMed Web of Science ®Google Scholar
• Szeimies RM, Calzavara-Pinton PG, Karrer S. Topical photodynamic therapy in dermatology. J Photochem Photobiol B. 1996;36:213–219.
   PubMed Web of Science ®Google Scholar
• Bissonnette R, Lui H. Current status of photodynamic therapy in dermatology. Dermatol Clin. 1997;15:507–519.
   PubMedGoogle Scholar
• Kennedy JC, Pottier RH. Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy. J Photochem Photobiol B. 1992;14:275–292.
   PubMed Web of Science ®Google Scholar
• Ormrod D, Jarvis B. Topical aminolevulinic acid HCl photodynamic therapy. Am J Clin Dermatol. 2000;1:133–139.
   PubMedGoogle Scholar
• Gupta AK, Ryder JE. Photodynamic therapy and topical aminolevulinic acid: an overview. Am J Clin Dermatol. 2003;4:699–708.
   PubMed Web of Science ®Google Scholar
• Boehncke WH, Sterry W, Kaufmann R. Treatment of psoriasis by topical photodynamic therapy with polychromatic light. Lancet. 1994;343:801.
   PubMed Web of Science ®Google Scholar
• Collins P, Robinson DJ, Stringer MR, Stables GI, Sheehan-Dare RA. The variable response of plaque psoriasis after a single treatment with topical 5-aminolaevulinic acid photodynamic therapy. Br J Dermatol. 1997;137:743–749.
   PubMed Web of Science ®Google Scholar
• Radakovic-Fijan S, Blecha-Thalhammer U, Schleyer V, Szeimies RM, Zwingers T, Hönigsmann H, et al. Topical Aminlaevulinic acid-based photodynamic therapy as a treatment option for psoriasis? Results of a randomized, observer- blinded study. Br J Dermatol. 2005;152:279–283.
   PubMed Web of Science ®Google Scholar
• Schleyer V, Radakovic-Fijan S, Karrer S, Zwingers T, Tanew A, Landthaler M, et al. Disappointing results and low tolerability of photodynamic therapy with topical 5- aminolaevulinic acid in psoriasis. A randomized, double-blind phase I/II study. J Eur Acad Dermatol Venereol. 2006;20:823–828.
   PubMed Web of Science ®Google Scholar
• Smits T, Kleinpenning MM, van Erp PE, van de Kerkhof PC, Gerritsen MJ. A Placebo controlled randomized study on the clinical effectiveness, immunohistochemical changes and protoporphyrin IX accumulation in fractionated 5-aminolaevulinic acid-photodynamic therapy in patients with psoriasis. Br J Dermatol. 2006;155:429–436.
   PubMed Web of Science ®Google Scholar
• Tandon YK, Yang MF, Baron ED. Role of photodynamic therapy in psoriasis: a brief review. Photodermatol Photoimmunol Photomed. 2008;24:222–230.
   PubMed Web of Science ®Google Scholar
• Bissonnette R, Tremblay JF, Juzenas P, Boushira M, Lui H. Systemic photodynamic therapy with aminolevulinic acid induces apoptosis in lesional T lymphocytes of psoriatic plaques. J Invest Dermatol. 2002;119:77–83.
   PubMed Web of Science ®Google Scholar
• Cappugi P, Mavilia L, Campolmi P, Reali EF, Mori M, Rossi R. New proposal for the treatment of nodular basal cell carcinoma with intralesional 5-sminolevulinic acid. J Chemother. 2004;16:491–493.
   PubMed Web of Science ®Google Scholar
• Lancu L, Shneur A, Cohen H. Trials with xanthine derivatives in systemic treatment of psoriasis. Dermatologica. 1979;159:55–61.
   PubMedGoogle Scholar
• Golchai J, Kishavars D. Treatment of psoriasis with topical aminophylline. Int J Dermatol. 1994;33:885.
   PubMed Web of Science ®Google Scholar
• Rusin LJ, Duell EA, Voorhees JJ. Papaverine and Ro 20–1724 inhibit cyclic nucleotide phosphodiesterase activity and increase cyclic AMP levels in psoriatic epidermis in vitro. J Invest Dermatol. 1978;71:154–156.
   PubMed Web of Science ®Google Scholar
• Iizuka H, Adachi K, Halprin KM, Levine V. Cyclic AMP accumulation in psoriatic skin: differential responses to histamine, AMP, and einephrine by the uninvolved and involved epidermis. J Invest Dermatol. 1978;70:250–253.
   PubMedGoogle Scholar
• Schork A, Duell EA, Voorhees JJ. Papaverine: its effects on cyclic AMP in vitro and psoriasis in vivo. J Invest Dermatol. 1975;64:124–127.
   PubMedGoogle Scholar
• Kerl K, Prins C, Saurat JH, French LE. Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and followup of eight cases. Br J Dermatol. 2006;155:1197–1200.
   PubMed Web of Science ®Google Scholar
• Fink-Puches R, Wolf IH, Zalaudek I, Kerl H, Cerroni L. Treatment of primary cutaneous B-cell lymphoma with rituximab. J Am Acad Dermatol. 2005;52:847–853.
   PubMed Web of Science ®Google Scholar
• Aboulafia DM. Primary cutaneous large B-cell lymphoma of the legs: a distinct clinical pathologic entity treated with CD20 monoclonal antibody (rituximab). Am J Clin Oncol. 2001;24:237–240.
   PubMed Web of Science ®Google Scholar
• Moberg P, Charles JF, Respicio G, Venna SS, Rooney T. Improvement in psoriasis during rituximab therapy for mixed cryoglobulinemia type II. Cutis. 2010;86:133–135.
   PubMedGoogle Scholar
• Dass S, Vital EM, Emery P. Development of psoriasis after B cell depletion with rituximab. Arthritis Rheum. 2007;56:2715–2718.
   PubMed Web of Science ®Google Scholar
• Markatseli TE, Kaltsonoudis ES, Voulgari PV, Zioga A, Drosos AA. Induction of psoriatic skin lesions in a patient with rheumatoid arthritis treated with rituximab. Clin Exp Rheumatol. 2009;27:996–998.
   PubMedGoogle Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–2342.
   PubMed Web of Science ®Google Scholar
• Costagliola C, Cipollone U, Rinaldi M, della Corte M, Semeraro F, Romano MR. Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma: a survey on 23 cases throughout 12-month follow-up. Br J Clin Pharmacol. 2008;66:667–673.
   PubMedGoogle Scholar
• Rotsos T, Sagoo MS, daCruz L, Andrews R, Dowler J. Intravitreal anti-VEGF treatment in eyes with combined choroidal neovascularisation and vitreomacular traction syndrome. Br J Ophthalmol. 2010;94:1205–1210.
   PubMedGoogle Scholar
• Jonas JB, Ihloff AK, Harder B, Kreissig I, Schlichtenbrede F, Libondi T, et al. Intravitreal bevacizumab versus triamcinolone acetonide for exudative age-related macular degeneration. Ophthalmic Res. 2009;41:21–27.
   PubMed Web of Science ®Google Scholar
• Akman A, Yilmaz E, Mutlu H, Ozdogan M. Complete remission of psoriasis following bevacizumab therapy for colon cancer. Clin Exp Dermatol. 2009;34:e202–e204.
   PubMed Web of Science ®Google Scholar
• Strieter RM, Remick DG, Ward PA, Spengler RN, Lynch JP 3rd,, Larrick J, et al. Cellular and molecular regulation of tumour necrosis factor alpha production by pentoxifylline. Biochem Biophys Res Commun. 1988;155:1230–1236.
   PubMed Web of Science ®Google Scholar
• Omulecki A, Broniarczyk-Dyła G, Zak-Prelich M, Choczaj-Kukuła A. Is pentoxifylline effective in the treatment of psoriasis? J Am Acad Dermatol. 1996;34:714–715.
   PubMed Web of Science ®Google Scholar
• Gilhar A, Grossman N, Kahanovicz S, Reuveni H, Cohen S, Eitan A. Antiproliferative effect of pentoxifylline on psoriatic and normal epidermis. In vitro and in vivo studies. Acta Derm Venereol. 1996;76:437–441.
   PubMed Web of Science ®Google Scholar
• el-Mofty M, el-Darouti M, Rasheed H, Bassiouny DA, Abdel-Halim M, Zaki NS, et al. Sulfasalazine and pentoxifylline in psoriasis: a possible safe alternative. J Dermatolog Treat. 2011;22:31–37.
   PubMed Web of Science ®Google Scholar
• Isaac C, Carvalho VF, Paggiaro AO, de Maio M, Ferreira MC. Intralesional pentoxifylline as an adjuvant treatment for perioral post-burn hypertrophic scars. Burns. 2010;36:831–835.
   PubMed Web of Science ®Google Scholar
• Duncan MR, Hasan A, Berman B. Pentoxyfilline and interferon decrease type I and III procollagen mRNA levels in dermal fibroblasts: evidence for mediation by nuclear factor 1 down-regulation. J Invest Dermatol. 1995;104:282–286.
   PubMedGoogle Scholar